日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PML mutants from arsenic-resistant patients reveal SUMO1-TOPORS and SUMO2/3-RNF4 degradation pathways.

来自抗砷患者的 PML 突变体揭示了 SUMO1-TOPORS 和 SUMO2/3-RNF4 降解途径

Jaffray Ellis G, Tatham Michael H, Mojsa Barbara, Plechanovová Anna, Rojas-Fernandez Alejandro, Liu Julio C Y, Mailand Niels, Ibrahim Adel F M, Ball Graeme, Porter Iain M, Hay Ronald T

Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND

与既往治疗方案相比,Axicabtagene Ciloleucel 治疗复发/难治性亚洲裔弥漫性大B细胞淋巴瘤的疗效:ZUMA-1 与 REAL-TREND 匹配调整间接比较研究

Locke, Frederick L; Ball, Graeme; Ray, Markqayne D; Li, Tony; Limbrick-Oldfield, Eve H; Popoff, Evan; Kanters, Steve

Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan

复发/难治性滤泡性淋巴瘤患者和医生的治疗偏好:一项在美国、英国、法国、德国、巴西和日本开展的离散选择实验

Gribben, John G; Bachy, Emmanuel; Ray, Markqayne; Krupsky, Kathryn; Beusterien, Kathleen; Kopenhafer, Lewis; Beygi, Sara; Best, Timothy; Ball, Graeme; Will, Oliver; Palivela, Madhu; Patel, Anik; Ghione, Paola

Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data

卫生技术再评估:利用长期临床试验数据解决肿瘤药物报销时经济评价的不确定性

Ball, Graeme; Levine, Mitchell A H; Thabane, Lehana; Tarride, Jean-Eric

Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis

滤泡性淋巴瘤患者在接受≥2线既往治疗后复发/难治性治疗的临床结局:系统性文献综述和荟萃分析

Kanters, Steve; Ball, Graeme; Kahl, Brad; Wiesinger, Adriana; Limbrick-Oldfield, Eve H; Sudhindra, Akshay; Snider, Julia Thornton; Patel, Anik R

Founder cell configuration drives competitive outcome within colony biofilms

创始细胞的构型决定了菌落生物膜内的竞争结果

Eigentler, Lukas; Kalamara, Margarita; Ball, Graeme; MacPhee, Cait E; Stanley-Wall, Nicola R; Davidson, Fordyce A

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada

在加拿大,Brexucabtagene Autoleucel 与最佳支持治疗相比,在接受布鲁顿酪氨酸激酶抑制剂治疗后复发/难治性套细胞淋巴瘤的治疗中具有成本效益。

Ball, Graeme; Lemieux, Christopher; Cameron, David; Seftel, Matthew D

Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia

加拿大、英国和澳大利亚的卫生技术评估机构对作为肿瘤治疗报销文件一部分提交的经济评价的评估:证据

Ball, Graeme; Levine, Mitchell A H; Thabane, Lehana; Tarride, Jean-Eric

Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology

不断进步:肿瘤学经济评价方法的系统性综述

Ball, Graeme; Levine, Mitch; Thabane, Lehana; Tarride, Jean-Eric

BIAFLOWS: A Collaborative Framework to Reproducibly Deploy and Benchmark Bioimage Analysis Workflows

BIAFLOWS:用于可重复部署和基准测试生物图像分析工作流程的协作框架

Rubens, Ulysse; Mormont, Romain; Paavolainen, Lassi; Bäcker, Volker; Pavie, Benjamin; Scholz, Leandro A; Michiels, Gino; Maška, Martin; Ünay, Devrim; Ball, Graeme; Hoyoux, Renaud; Vandaele, Rémy; Golani, Ofra; Stanciu, Stefan G; Sladoje, Natasa; Paul-Gilloteaux, Perrine; Marée, Raphaël; Tosi, Sébastien